RUNX1 mutation

News alerts, weekly reports and conference planners

Entrez ID:

861

Related biomarkers:

‹

›

RUNX1 mutation	Myelodysplastic Syndrome	RUNX1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
RUNX1 mutation	Chronic Myelomonocytic Leukemia	RUNX1 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
RUNX1 mutation	Myelodysplastic Syndrome	RUNX1 mutation	Myelodysplastic Syndrome	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
RUNX1 mutation	Myelodysplastic Syndrome	RUNX1 mutation	Myelodysplastic Syndrome	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	venetoclax + RO5503781 Sensitive: C3 – Early Trials venetoclax + RO5503781 Sensitive : C3	venetoclax + RO5503781 Sensitive: C3 – Early Trials venetoclax + RO5503781 Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3
RUNX1 mutation	Myelodysplastic Syndrome	RUNX1 mutation	Myelodysplastic Syndrome	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	CDIAG Sensitive: C3 – Early Trials CDIAG Sensitive : C3	CDIAG Sensitive: C3 – Early Trials CDIAG Sensitive : C3
RUNX1 mutation	Chronic Myeloid Leukemia	RUNX1 mutation	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	BTX-A51 Sensitive: C3 – Early Trials BTX-A51 Sensitive : C3	BTX-A51 Sensitive: C3 – Early Trials BTX-A51 Sensitive : C3
RUNX1 mutation	Myelodysplastic Syndrome	RUNX1 mutation	Myelodysplastic Syndrome	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	HAG + azacitidine Sensitive: C3 – Early Trials HAG + azacitidine Sensitive : C3	HAG + azacitidine Sensitive: C3 – Early Trials HAG + azacitidine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	tagraxofusp Sensitive: D – Preclinical tagraxofusp Sensitive : D	tagraxofusp Sensitive: D – Preclinical tagraxofusp Sensitive : D

RUNX1 mutation

Associations